CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Christina Morrison to its Board of Directors effective immediately. Most recently, Ms. Morrison served as the Senior Vice President of Finance for Aramark, where she was responsible for treasury, including oversight of over $5 billion of debt, global shared services, which processes certain accounting functions as well as certain human resource functions for over 120,000 employees, and mergers & acquisitions. She joined Aramark in June 2013 as Senior Vice President of Finance.
Prior to joining Aramark, Ms. Morrison was Senior Vice President of Business and Financial Planning at Merck & Co., Inc. from November 2009 to June 2013. She was responsible for the company-wide planning, forecasting and budgeting processes, data and process standardization, and developing more automated reporting capabilities.
Ms. Morrison’s previous experience includes five years at Wyeth, beginning in April 2004, as the Vice President of New Business in the Women’s Health Care division. In November 2005, she was appointed Vice President and Chief Financial Officer for Wyeth U.S. Pharmaceuticals, and in July 2007, she was promoted to Senior Vice President and Chief Financial Officer for Wyeth Pharmaceuticals. In that role, she was responsible for the global planning and reporting of the $20 billion pharmaceutical division. Ms. Morrison started her career as an analyst in the Mergers and Acquisitions Department at Alex. Brown & Sons, an investment bank (now Deutsche Bank). During her 12 years at Deutsche Bank, she held increasingly responsible positions, her last being Managing Director, Health Care Group.
Ms. Morrison has been a member of the Board of Overseers of the Tuck School of Business at Dartmouth College since May 2011. She has also been a Member of the Board of Angel Flight East, a non-profit organization, since May 2014.
Ms. Morrison graduated cum laude from the Wharton School at the University of Pennsylvania with a Bachelor of Science degree in Economics in 1989 and the Tuck School of Business at Dartmouth College in 1993 with an MBA.
Mark Perrin, InVivo’s CEO and Chairman, said, “We are committed to building a world-class Board of Directors with seasoned executives so that we can draw upon their diverse insights and experiences as InVivo continues to succeed and grow. The Board is pleased to welcome Christina, and we look forward to benefiting from her impressive background and expertise.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
